Li X - Search Results

1

Potent Hydrazide-Based HDAC Inhibitors with a Superior Pharmacokinetic Profile for Efficient Treatment of Acute Myeloid Leukemia In Vivo.

Jiang Y, Xu J, Yue K, Huang C, Qin M, Chi D, Yu Q, Zhu Y, Hou X, Xu T, Li M, Chou CJ, Li X. Jiang Y, et al. Among authors: li x, li m. J Med Chem. 2022 Jan 13;65(1):285-302. doi: 10.1021/acs.jmedchem.1c01472. Epub 2021 Dec 23. J Med Chem. 2022. PMID: 34942071

2

Progress of HDAC inhibitor panobinostat in the treatment of cancer.

Li X, Zhang J, Xie Y, Jiang Y, Yingjie Z, Xu W. Li X, et al. Curr Drug Targets. 2014 Jun;15(6):622-34. doi: 10.2174/1389450115666140306152642. Curr Drug Targets. 2014. PMID: 24597570 Review.

3

Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.

Li X, Inks ES, Li X, Hou J, Chou CJ, Zhang J, Jiang Y, Zhang Y, Xu W. Li X, et al. J Med Chem. 2014 Apr 24;57(8):3324-41. doi: 10.1021/jm401877m. Epub 2014 Apr 15. J Med Chem. 2014. PMID: 24694055 Free PMC article.

4

Design, synthesis and preliminary evaluation of α-sulfonyl γ-(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors.

Zhang J, Li X, Jiang Y, Feng J, Li X, Zhang Y, Xu W. Zhang J, et al. Among authors: li x. Bioorg Med Chem. 2014 Jun 1;22(11):3055-64. doi: 10.1016/j.bmc.2013.12.025. Epub 2013 Dec 21. Bioorg Med Chem. 2014. PMID: 24755524

5

HDAC1/3 dual selective inhibitors - new therapeutic agents for the potential treatment of cancer.

Li X, Xu W. Li X, et al. Drug Discov Ther. 2014 Oct;8(5):225-8. doi: 10.5582/ddt.2014.01034. Drug Discov Ther. 2014. PMID: 25382558 Free article. Review.

6

Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.

Li X, Hou J, Li X, Jiang Y, Liu X, Mu W, Jin Y, Zhang Y, Xu W. Li X, et al. Eur J Med Chem. 2015 Jan 7;89:628-37. doi: 10.1016/j.ejmech.2014.10.077. Epub 2014 Oct 29. Eur J Med Chem. 2015. PMID: 25462271

7

Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.

Duan W, Li J, Inks ES, Chou CJ, Jia Y, Chu X, Li X, Xu W, Zhang Y. Duan W, et al. Among authors: li j, li x. J Med Chem. 2015 May 28;58(10):4325-38. doi: 10.1021/acs.jmedchem.5b00317. Epub 2015 May 7. J Med Chem. 2015. PMID: 25906087 Free PMC article.

8

Correction to Design, Synthesis, and Antitumor Evaluation of Novel Histone Deacetylase Inhibitors Equipped with a Phenylsulfonylfuroxan Module as a Nitric Oxide Donor.

Duan W, Li J, Inks ES, Chou CJ, Jia Y, Chu X, Li X, Xu W, Zhang Y. Duan W, et al. Among authors: li j, li x. J Med Chem. 2015 Aug 13;58(15):6319. doi: 10.1021/acs.jmedchem.5b01075. Epub 2015 Jul 30. J Med Chem. 2015. PMID: 26225799 No abstract available.

9

Development of N-hydroxybenzamide derivatives with indole-containing cap group as histone deacetylases inhibitors.

Li X, Wu J, Li X, Mu W, Liu X, Jin Y, Xu W, Zhang Y. Li X, et al. Bioorg Med Chem. 2015 Oct 1;23(19):6258-70. doi: 10.1016/j.bmc.2015.08.040. Epub 2015 Aug 29. Bioorg Med Chem. 2015. PMID: 26349626

10

Discovery of Multi-target Anticancer Agents Based on HDAC Inhibitor MS-275 and 5-FU.

Jiang Y, Li X, Li X, Hou J, Ding Y, Zhang J, Xu W, Zhang Y. Jiang Y, et al. Among authors: li x. Med Chem. 2016;12(1):30-6. doi: 10.2174/1573406411666150714111045. Med Chem. 2016. PMID: 26711240

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

183,004 results

Search Page

Filters